

# Simple and Rapid Identification of Low Level Hepatitis B Virus DNA by the Nested Polymerase Chain Reaction

Jeong Su Jang<sup>1</sup> and Kong-Joo Lee\*

\*College of Pharmacy, Ewha Womans University, Seoul 120-750, Korea and <sup>1</sup>General Institute of Technology, Hyundai Pharm, Ind. Co., LTD, Bucheon 422-231, Korea

(Received August 1, 1996)

A rapid and sensitive method has been developed to detect hepatitis B virus DNA (HBV) by nested polymerase chain reaction (PCR) technique with primers specific for the surface and core regions in capillary thermal cycler within 80 min. The lower limit for detection by present PCR method is  $10^{-5}$  pg of recombinant HBV DNA which is equivalent to that determined by one round of PCR amplification and Southern blot hybridization analysis. When boiled HBV positive serum was serially diluted 10-fold, HBV DNA was successfully determined in  $1 \mu\text{l}$ - $10^{-3} \mu\text{l}$  of serum. HBV DNA was detected by present method in 69 clinical samples including HBsAg positives and negatives by enzyme-linked immunosorbent assay (ELISA). When serum samples were amplified by nested PCR using surface and core region primers, HBV DNAs were detected in 37 of 69 samples (53.6%) and 18 of 69 samples (26.1%), respectively. These results can inform the infectious state of HBsAg positive patients. A simple and rapid nested PCR protocol by using boiled serum as DNA template has been described for the clinical utility to determine HBV DNA in human serum.

**Key words :** Hepatitis B Virus, Nested PCR, Boiling of serum, Sensitive detection, Rapid identification

## INTRODUCTION

The amplification of hepatitis B virus (HBV) DNA sequences in sera for molecular epidemiology of HBV is an important application of the polymerase chain reaction (PCR) with regard to HBV. Immunoassays for hepatitis B surface antigen (HBsAg) and hepatitis B envelop antigen (HBeAg) are unable to detect viral associated antigen at the concentration at the limit of infectivity: only few viruses per ml. One step PCR for HBV DNA can only detect 0.1 to 1 pg (2,500 to 25,000 viruses). While some HBsAg positive patients may not be actively producing virus and are not infectious, it is difficult to distinguish these individuals from patients who have low levels of viral replication. For the sensitive detection, previous investigations with PCR technique have shown to detect  $10^{-5}$  pg of HBV DNA (Kaneko *et al.*, 1989a and b) by one round of PCR amplification and Southern blot hybridization analysis. A single step DNA extraction procedure using guanidium thiocyanate and phenol as protein denaturants for the detection of specific HBV DNA is described (Manzin *et al.*, 1991). For the simple procedure, whole blood samples pre-

treated with anticoagulants, freeze and thawing have been used as HBV templates without further purification of DNA (Burckhardt, 1994). In this study, boiled serum without DNA extraction was used as HBV DNA template for PCR, and various combinations of primer sets in core and surface region were employed for nested PCR using capillary thermal cycler. The results demonstrate that the fast and sensitive nested PCR method for detecting HBV DNA in the sera of HBsAg positive patients and negative normal blood donors can be a possible tool for detecting the infectious state in clinical measurement.

## MATERIALS AND METHODS

### Materials

Serum samples were obtained from Blood Bank (Daejeon, Korea) and Korea Research Institute of Standards and Science. Out of 69 sera, 46 were positives for HBsAg by an enzyme-linked immunosorbent assay (ELISA) (Organon Teknika B.V., Boxtel, Holland). All sera were stored at  $-70^{\circ}\text{C}$ . Oligonucleotide primers, specific for the most conserved surface (surface primers) and core gene sequences (core primers) of HBV genome were synthesized using a DNA synthesizer (Oligos Etc. Inc., USA). These were chosen

Correspondence to: Kong-Joo Lee, College of Pharmacy, Ewha Womans University, Seoul, Korea, 120-750

**Table 1.** Oligonucleotide sequences used for detection of serum HBV DNA

Region	Primer	Sequence (5' to 3')	Nucleotide position <sup>a</sup>	Product size
<i>surface</i>				
	outer primers			532 bp
	BSO1	-GACAAGAATCCTCACAATACC-	93-113	
	BSO2	-ACCACATCATCCATATAACTGAAAG-	625-601	
	inner primers			297 bp
	BSI1	-ACCTCCAATCACTCACCAACC-	196-216	
	BSI2	-AGGATGATGGGATGGGAATA-	493-474	
	probe			
	BSPB	-GTGTCTGCGGCGTTTTATCAT-	252-272	
<i>core</i>				
	BCO1	-TCTCTGTTCATGTCCTACTGTTC-	1714-1737	
	BCO2	-AAGCTGGAGGAGTGCGAATC-	2166-2147	
	BCO3	-AAAAGACACCAAATACTCTAGAA-	2138-2116	
	BCO4	-TCGTCGTCTAACAACAGTAGT-	2228-2208	
	BCI1	-TTACTCTCTTTTTGCCTTCTGAC-	1815-1838	
	BCI2	-AGACAAGAAATGTGAAACCAC-	2095-2075	

<sup>a</sup>Nucleotide positions are numbered as A. Fujiyama *et al.* (3).

by comparison with available nucleotide sequences from Hepadnaviruses (subtype *adr*, *adw*, and *ayw*) in order to define different sets of conserved DNA sequences to be used as primers (Table 1).

#### DNA preparation by boiling method

For obtaining the template DNA from human serum, 20 µl of serum was boiled at 94°C for 3 min, cooled rapidly in ice, and diluted with 40 µl of sterile water. After centrifugation at 12,000 rpm for 5 min, the supernatant was employed as DNA template. The 1st PCR amplifications were carried out in 10 µl reaction mixtures containing 3 µl of template, 200 µM each dNTP, 0.5 µM each outer primer, 0.4 U of *Taq* DNA polymerase and 1x RT-PCR buffer (10x buffer consists of 500 mM Tris-HCl (pH 8.3), 200 mM KCl, 30 mM MgCl<sub>2</sub>, 5% dimethylsulfoxide, and 2.5 mg/ml bovine serum albumin). The reactions were performed in FTC 2000 capillary thermal cycler (Daehan Medical Co., Korea) which was developed for use in clinical application because of its fast PCR reaction (30~35 min for 30 cycles) using glass capillary with air flow system without a mineral oil overlay. The 1st PCR reaction proceeded with 30 cycles at 94°C for 5 s, 50°C for 10 s and 72°C for 15 s. The 2nd PCR amplifications (30 cycles) were carried out in 10 µl reaction mixtures containing 1 µl of the 1st PCR product, 200 µM each dNTP, 1.0 µM each inner primer and 0.4 U of *Taq* DNA polymerase. The PCR cycling conditions were same as those described in 1st PCR. Recombinant HBV DNA was used as positive control for PCR amplification and for establishing the lower detection limit of the assay. Recombinant plasmid pHBV-315 containing cloned HBV gene was a gift from Dr. M.H. Yu (Korea Research Institute of Bios-

science & Biotechnology, Korea) (Kim and Kang, 1984). HBV DNA was isolated from pHBV-315 by digestion with *Bam*HI followed by agarose gel electrophoresis and electroelution. For 2nd PCR, a 1 µl portion of the 1st PCR product was amplified as described in above boiling method. To eliminate sources of DNA contamination, reagents were all aliquoted and stored in new disposable containers. All experiments were performed in parallel with serum samples from positive, negative, and the reagent control without DNA.

#### Conventional DNA preparation method

To obtain the template DNA, 100 µl of human serum were incubated at 70°C for 3 hr in the presence of proteinase K (100 µg/ml), 0.5% sodium dodecyl sulfate (sds), 5 mM EDTA, and 10 mM Tris-HCl (pH 8.0). The solution was phenol/chloroform extracted, and the DNA was precipitated with ethanol in the presence of ammonium acetate (2.5 M) at -20°C for overnight. The precipitate was dissolved in 100 µl of sterile distilled water. The PCR amplifications were carried out in 10 µl reaction mixtures containing 5 µl of template. The other conditions were same as described in above boiling method.

#### Analysis of amplified DNA


For each sample, a 5 µl aliquot of the amplified DNA reaction mixture was analyzed by ethidium bromide staining after separation on 2% agarose gel electrophoresis. The specificity of the amplified bands was confirmed by Southern blot hybridization analysis using a [ $\gamma$ -<sup>32</sup>P] labeled BSPB probe. The DNA transferred to a nitrocellulose membrane was prehy-

bridized in 6x SSC (1x SSC is 0.15 M NaCl/0.015 M sodium citrate, pH 7.0)/5x Denhardt's solution/0.5% SDS containing denatured, fragmented salmon sperm DNA (100 µg/ml) at 42°C for 4 hr. The prehybridized filter was hybridized with labeled BSPB probe (10<sup>9</sup> cpm/µg) at 42°C for overnight. After hybridization, the membrane filter was washed twice in 2x SSC/0.1% SDS for 5 min at room temperature, two times in 0.1x SSC/0.1% SDS at 42°C for 30 min, and then two times in 0.1x SSC/0.1% SDS at 65°C for 5 min per wash. The filter was exposed for overnight at -70°C with X-ray film for autoradiography.

**RESULTS**

**The Sensitivity of the nested PCR technique**

The detection limit of HBV DNA was determined after PCR amplification using 10 fold serial dilutions of recombinant HBV DNA. First PCR products were separated by agarose gel electrophoresis and visual-




**Fig. 1.** Establishment of detection limits of the PCR technique with recombinant HBV DNA. Cloned HBV DNA were serially diluted and amplified with surface primers. The 1st PCR product with BSO1 and BSO2 was detected with (A) agarose gel electrophoresis and ethidium bromide staining or (B) Southern blot hybridization using [<sup>32</sup>P] labeled probe, and (C) nested PCR products with BSO1-BSO2/BSI1-BSI2 were detected with agarose gel electrophoresis and ethidium bromide staining. Lane 1, ΦX174 DNA/*Hae*III digest; lane 2, reagent control without DNA; lane 3, negative control; lane 4-12, serial 10-fold dilution of recombinant DNA ranging from 1 pg to 10<sup>-8</sup> pg DNA, respectively

ized under UV light by ethidium bromide fluorescence. Samples containing an initial quantity of recombinant HBV DNA being ≥ 10<sup>-2</sup> pg produced a visible DNA band of expected size (532 base pairs, bp) (Fig. 1A). When 1 µl of each amplified reaction mixture was reamplified with inner primers, a DNA band of 297 bp was detected in samples containing ≥ 10<sup>-5</sup> pg of HBV DNA before the 1st PCR amplification reaction (Fig. 1C). On the other hand, the 1st PCR products transferred to a nitrocellulose paper after agarose gel electrophoresis and ethidium bromide staining were hybridized to a [<sup>32</sup>P] labeled HBV DNA probe (BSPB) to compare the sensitivity of 1st PCR-Southern blot hybridization with nested PCR. The 1st PCR-Southern blot hybridization analysis could detect 10<sup>-5</sup> pg of HBV DNA in the original sample (Fig. 1B). Thus, the sensitivity of nested PCR is equivalent to that of 1st PCR-Southern blot hybridization.


When boiled HBV positive serum was serially diluted 10-fold, HBV DNA was successfully determined in 1 µl~10<sup>-3</sup> µl of serum using either surface primers (Fig. 1) or core primers (Fig. 2). This indicates that the sensitivity using boiled serum as DNA template without DNA extraction allows the detection of HBV DNA in a wide range of concentration.

**Detection of HBV DNA amplified from serum samples**

HBV DNA was detected by nested PCR using boiled serum in 69 clinical samples including HBsAg negatives (23 samples), and positives (46 samples) by ELISA test. Negative control sample and reagent control (no nucleic acid) were included in each set of amplification reaction to test the contamination (Fig. 3).



**Fig. 2.** HBV DNA detected with nested PCR using BCO1-BCO4/BCI1-BCO2 when the various amounts of boiled HBV positive serum were used as DNA template after dilution with sterile distilled water. A DNA band of 351 bp was detected in samples containing ≥ 10<sup>-1</sup> µl of boiled serum. Lane 1, pBR322/*Hinf*I digest; lane 2, 1 µl serum; lane 3, 0.5 µl serum; lane 4, 0.2 µl serum; lane 5-12, serial 10-fold dilutions of boiled serum ranging from 10<sup>-1</sup> to 10<sup>-8</sup> µl, respectively



**Fig. 3.** Detection of nested PCR products from 3 µl of boiled serum from HBsAg positive or negative serums using surface primers (A) and core primers (BCO1-BCO2/BCI1-BCI2) (B). Lane 1, pBR322/*Hinf*I digest; lane 2, reagent control without DNA template; lane 3, positive control serum; lane 4-6, HBsAg negative serums; lane 7-11, HBsAg positive serums; lane 12, negative control serum

HBV DNAs amplified using surface primers (Fig. 3A) were detected by PCR in 4 of 23 HBsAg negative samples (17.4%), 33 of 46 positive samples (71.7%). On the other hand, HBV DNAs amplified using core primers (Fig. 3B) were detected by PCR in 3 of 23 HBsAg negative samples (13.0%) and 15 of 46 positive samples (32.6%). Table II summarizes the results using various primer sets. When HBV DNA extracted with conventional method was detected by nested PCR in 69 clinical samples, the results were well agreed with those of the HBV DNA prepared by boiling method (data not shown).

**DISCUSSION**

Application of the nested PCR technique requires the selection of well conserved target sequences. Target sequences of the surface and core regions in HBV DNA were amplified with air-heated capillary based thermal cycler, FTC 2000. FTC 2000 has several advantages over the pre-existed thermal cyclers, i.e., 10-fold shorter thermal cycling time with hot air system (30~35 min *versus* 2~4 hr) and reducing the amounts of PCR reaction components (including primers, each dNTP, *Taq* DNA polymerase, *etc*) because of its small reaction volume. Use of shorter annealing and ramping times increase the specificity of priming and therefore raise the overall quality of the PCR reaction. The

**Table II.** Detection of serum HBV DNA by different primers

Serum sample number	HBsAg	Primer to			
		Surface gene BSO1-BSO2/BSI1-BSI2	BCO1-BCO2/BCI1-BCI2	Core gene BCO1-BCO3/BCI1-BCI2	BCO1-BCO4/BCI1-BCO2
1	+	+	-	-	-
2	+	+	-	-	-
3	+	+	+	+	+
4	+	+	+	+	+
5	+	+	+	+	+
6	+	+	+	+	+
7	+	+	-	-	-
8	+	+	-	-	-
9	+	+	-	-	-
10	+	+	-	-	-
11	+	+	-	-	-
12	+	+	-	-	-
13	+	+	+	+	+
14	+	+	-	-	-
15	+	+	+	+	+
16	+	+	+	+	+
17	+	+	-	-	-
18	+	+	+	+	+
19	+	+	+	+	+
20	+	+	-	-	-
21	+	+	+	+	+
22	+	+	-	-	-
23	+	+	-	-	-
24	+	+	-	-	-
25	+	+	-	-	-
26	+	+	-	-	-
27	+	+	+	+	+
28	+	-	+	+	+
29	+	-	+	+	+
30	+	-	+	+	+
31	+	-	+	+	+
32	+	-	-	-	-
33	+	-	-	-	-
34	+	-	-	-	-
35	+	-	-	-	-
36	+	-	-	-	-
37	+	-	-	-	-
38	+	-	-	-	-
39	+	-	-	-	-
40	+	-	-	-	-
41	+	-	-	-	-
42	+	-	-	-	-
43	+	-	-	-	-
44	+	-	-	-	-
45	+	-	-	-	-
46	+	-	-	-	-
47	-	-	-	-	-
48	-	-	-	-	-
49	-	-	-	-	-
50	-	-	-	-	-
51	-	-	-	-	-
52	-	-	-	-	-
53	-	-	-	-	-
54	-	-	-	-	-
55	-	-	-	-	-
56	-	+	+	+	+
57	-	+	+	+	+
58	-	+	+	+	+
59	-	-	-	-	-
60	-	-	-	-	-
61	-	-	-	-	-
62	-	-	-	-	-
63	-	-	-	-	-
64	-	+	-	-	-
65	-	-	-	-	-
66	-	-	-	-	-
67	-	-	-	-	-
68	-	-	-	-	-
69	-	-	-	-	-

NOTE: +, positive result; -, negative result

lower limit of detection of recombinant HBV DNA was determined as  $10^{-5}$  pg by nested PCR with surface primers. This sensitivity is equivalent to that by detection the 1st PCR product with radio labeled Southern blot hybridization (Kaneko *et al.*, 1989a and b).

HBV DNA in  $1 \mu\text{l}$ – $10^{-3} \mu\text{l}$  of serum prepared by present boiling method were amplified using either surface or core region primers. The detection limit of HBV DNA in  $10^{-3} \mu\text{l}$  serum corresponding to the  $10^{-5}$  pg was determined with recombinant HBV DNA.

When serum samples were amplified using surface and core region primers, HBV DNA were detected in 37 of 69 tested samples (53.6%) and 18 of 69 tested samples (26.1%), respectively. Not all HBsAg positive serums are HBV DNA positives similar to those reported by others (Zeldis *et al.*, 1989; Liang *et al.*, 1989; Zaaijer *et al.*, 1994; Scully *et al.*, 1994). On the other hand, HBV DNA detection (percentage of positives) using core primers are relatively low compared with those of surface primers as shown in Table II. This discrepancy might be caused either by a lower rate of viral replication leading to a reduced number of circulating HBV DNA or modifications of the viral genome (Chemin *et al.*, 1991; Okamoto *et al.*, 1990; Wright *et al.*, 1992; Liang *et al.*, 1991; Omata *et al.*, 1991; Persing *et al.*, 1986; Koh *et al.*, 1995) rather than the problem of the sensitivity (both  $10^{-3} \mu\text{l}$  of serum). The core region primer sets BCO1-BCO2/BCI1-BCI2, were used initially and two other core region primers, BCO3 and BCO4, covering a wide range of the core gene were employed to solve this difference. By adopting various combination of six core region primers as shown in Table II, the identical results for 69 serum samples were acquired. The deviations between serological method and nested PCR method using surface and core region primers can be explained by further investigation on the correlation between HBV serological markers (anti-HBs, anti-HBc, HBeAg, Anti-HBe, etc) and clinical traits of the HBV infection as a function of infectious stage, and the nucleotide sequence determination. In this respect, primers used in this experiments can be utilized for differentiating HBV genotypes (Norder *et al.*, 1990). The results demonstrate that HBV DNA detection by nested PCR should be done for the different regions on the HBV viral genome, for example, surface and core region, to obtain the information on the infectious state of HBV similar as those of the serological determination of HBV infection.

Despite its powerful technique as a diagnostic tool for clinical samples, a major problem in PCR is the ease of contaminating target sequences from samples and reagents by carryover in PCR (Kwok and Higuchi, 1989). The precaution should be exercised to control contamination risks. The reagent control and negative control were included in each set of PCR am-

plification. When performing nested PCR with surface and core region primers, contaminations by carryover were not occurred in the various conditions of MATERIALS AND METHODS. Nested PCR eliminating the carryover is a sensitive method to detect low level of HBV DNA (few viruses). Rapid protocols of nested PCR for the clinical laboratory are possible to adopt air-heated capillary thermal cycler (FTC 2000) and to use boiled serum as DNA template without DNA extraction. The rapidity and high sensitivity of the nested PCR using various primer sets for detecting HBV DNA in clinical samples should facilitate diagnostic assays for detecting viral DNA in various infectious conditions and may give information on the biology of HBV.

## ACKNOWLEDGMENT

We grateful to Dr. M.H. Yu in Korea Research Institute of Biosciences and Biotechnology (KRIBB) for kindly providing the recombinant HBV DNA. This work was supported by Korean Ministry of Science and Technology.

## REFERENCES CITED

- Burckhardt, J., Amplification of DNA from whole blood. *PCR Methods Appl.*, 3, 239-243 (1994)
- Chemin, I., Baginski, I., Petit, M. A., Zoulim, F., Pichoud, C., Capel, F., Hantz, O. and Trepo, C., Correlation between HBV DNA detection by polymerase chain reaction and pre-S1 antigenemia in symptomatic and asymptomatic hepatitis B virus infections. *J. Med. Virol.*, 33, 51-57 (1991).
- Fujiyama, A., Miyanohara, A., Nozaki, C., Yoneyama, T., Ohtomo, N. and Matsubara, K., Cloning and structural analyses of hepatitis B virus DNAs, subtype adr. *Nucleic Acids Res.*, 11, 4601-4610 (1983).
- Kaneko, S., Miller, R., Feinstone, S., Unoura, M., Kobayashi, K., Hattori, N. and Purcell, R. H., Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. *Proc. Natl. Acad. Sci. USA.*, 86, 312-316 (1989).
- Kaneko, S., Feinstone, S. M. and Miller, R. H., Rapid and sensitive method the detection of serum hepatitis B virus DNA using the polymerase chain reaction technique. *J. Clin. Microbiol.*, 27, 1930-1933 (1989).
- Kim, Y. S. and Kang, H. S., Cloning and expression of hepatitis B virus surface antigen gene. *Korean. Biochem. J.*, 17, 70-79 (1984).
- Koh, K. C., Lee, H. S. and Kim, C. Y., Association of the core clustering mutations (codon 21-34) and the severity of chronic hepatitis B in Korean pa-

- tients. *Korean J. Intern. Med.*, 10, 87-93 (1995)
- Kwok, S. and Higuchi, R., Avoiding false positives with PCR. *Nature*, 339, 237-238 (1989).
- Liang, T. J., Hasegawa, K., Rimon, N., Wands, J. R. and Ben-Porath, E., A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. *N. Engl. J. Med.*, 324, 1705-1709 (1991).
- Liang, T. J., Iseibacher, K. J. and Wands, J. R., Rapid identification of low level hepatitis B-related viral genome in serum. *J. Clin. Invest.*, 84, 1367-1371 (1989).
- Manzin, A., Salvoni, G., Bagnarelli, P., Menzo, S., Carloni, G. and Clement, M., A single step DNA extraction procedure for the detection of serum hepatitis B virus. *J. Virol. Methods*, 32, 245-253 (1991)
- Norder, H., Hammas, B. and Magnius, L. O., Typing of hepatitis B virus genomes by a simplified polymerase chain reaction. *J. Med. Virol.*, 31, 215-221 (1990).
- Okamoto, H., Yotsomuto, S., Akahane, Y., Yamanaka, T., Miyazaki, Y., Sugai, F., Tanaka, T., Miyakawa, Y. and Mayumi M., Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. *J. Virol.*, 64, 1298-303 (1990).
- Omata, M., Ehata, T., Yokosuka, O., Hosoda, K. and Ohto, M., Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. *N. Engl. J. Med.*, 324, 1699-1704 (1991).
- Persing, D. H., Varmus, H. E. and Ganem, D., Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide. *Science*, 234, 1388-1391 (1986).
- Scully, L. J., Sung, H., Pennie, R. and Gill, P., Detection of hepatitis B virus DNA in the serum of Canadian hepatitis B surface antigen negative, anti-HBe positive individuals, using the polymerase chain reaction. *J. Med. Virol.*, 44, 293-297 (1994)
- Wright, T. L., Mamish, D., Combs, C., Kim, M., Donegan, E., Ferrell, L., Lake, J., Roberts, J. and Ascher, N. L., Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. *Lancet*, 339, 952-955 (1992).
- Zaaijer, H. L., ter Borg, F., Cuypers, H. T., Hermus, M. C. and Lelie, P. N., Comparison of methods for detection of hepatitis B virus DNA. *J. Clin. Microbiol.*, 32, 2088-2091 (1994)
- Zeldis, J. B., Lee, J. H., Mamish, D., Finegold, D. J., Sircar, R., Ling, Q., Knudsen, P. J., Kuramoto, I. K. and Mimms, L. T., Direct method for detecting small quantities of hepatitis B virus DNA in serum and plasma using the polymerase chain reaction. *J. Clin. Invest.*, 84, 1503-1508 (1989).